ArticleBMC medicine2023
The Full Value of Vaccine Assessments (FVVA): a framework for assessing and communicating the value of vaccines for investment and introduction decision-making.
Article in BMC medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed.
- Maternal Influenza Vaccine Reduces the Risk of Respiratory Syncytial Virus and Related Respiratory Hospitalizations in Early Infancy: An Epidemiological Study.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Article
- The use of deliberative dialogue in health services research: a scoping review.Research involvement and engagement · 2026Review
- Immunotherapeutic modalities for combating multidrug-resistant bacteria: therapeutic promises of antibodies and next-generation vaccines.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Estimating the Value of Combination Vaccines: A Methodological Framework.PharmacoEconomics · 2026Review
- Introducing an Expanded Value Framework in Health Technology Assessment of Vaccines.Journal of market access & health policy · 2026Article
- Taxonomy of the Full Health and Societal Value of Maternal Vaccination to Prevent Infant Respiratory Syncytial Virus Disease.Infectious diseases and therapy · 2026Review
- Estimating the population impact of new tuberculosis vaccines depending on efficacy against infectious asymptomatic tuberculosis: A modelling study.PLoS medicine · 2026Article
- Evaluation of rotavirus, pneumococcal conjugate and human papillomavirus vaccination in four Pacific island countries: A cost-effectiveness modelling study.PLoS medicine · 2026Article
- Country-level perspectives and priorities to guide the development of Invasive non-Typhoidal Salmonella (iNTS) vaccines: Insights from seven countries.PLoS neglected tropical diseases · 2026Article
- Vaccine Development, Its Implementation and Price Setting: A Historical Perspective with Proposed Ways to Move Forward.Journal of market access & health policy · 2025Article
- Review
- A systematised review and evidence synthesis on the broader societal impact of vaccines against Salmonella.NPJ vaccines · 2025Article
- Cost-Effectiveness Analysis of Hepatitis E Vaccination Strategies for Swine Workers.Transboundary and emerging diseases · 2025Article
- Health and economic impacts of Lassa vaccination campaigns in West Africa.Nature medicine · 2024Article
- Article
- Health impact and cost-effectiveness of vaccination using potential next-generation influenza vaccines in Thailand: a modelling study.BMJ global health · 2024Article
- A Structured Narrative Literature Review of the Broader Value of Adult Immunisation Programmes.Vaccines · 2024Review
- Vaccine value profile for Chikungunya.Vaccine · 2024Article
- The Value of Flexible Vaccine Manufacturing Capacity: Value Drivers, Estimation Methods, and Approaches to Value Recognition in Health Technology Assessment.PharmacoEconomics · 2024Review
- Facilitating the development of urgently required combination vaccines.The Lancet. Global health · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundSeveral economic obstacles can deter the development and use of vaccines. This can lead to limited product options for some diseases, delays in new product development, and inequitable access to vaccines. Although seemingly distinct, these obstacles are actually interrelated and therefore need to be addressed through a single over-arching strategy encompassing all stakeholders.
methodsTo help overcome these obstacles, we propose a new approach, the Full Value of Vaccines Assessments (FVVA) framework, to guide the assessment and communication of the value of a vaccine. The FVVA framework is designed to facilitate alignment across key stakeholders and to enhance decision-making around investment in vaccine development, policy-making, procurement, and introduction, particularly for vaccines intended for use in low- and middle-income countries.
resultsThe FVVA framework has three key elements. First, to enhance assessment, existing value-assessment methods and tools are adapted to include broader benefits of vaccines as well as opportunity costs borne by stakeholders. Second, to improve decision-making, a deliberative process is required to recognize the agency of stakeholders and to ensure country ownership of decision-making and priority setting. Third, the FVVA framework provides a consistent and evidence-based approach that facilitates communication about the full value of vaccines, helping to enhance alignment and coordination across diverse stakeholders.
conclusionsThe FVVA framework provides guidance for stakeholders organizing global-level efforts to promote investment in vaccines that are priorities for LMICs. By providing a more holistic view of the benefits of vaccines, its application also has the potential to encourage greater take-up by countries, thereby leading to more sustainable and equitable impacts of vaccines and immunization programmes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.